Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT01617655

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01617655
  • EudraCT 2012-001096-37
Other papers using this trial's data
  • Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher Cardiovascular drugs and therapy, 2016-10 DOI, PubMed 27618825, PMC5055560 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Netherlands, Russia, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01617655. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-11-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
Condition
Hypercholesterolaemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Lipid Modifying Therapy (LMT)
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01617655
Content hash
5c13e5c5df173139617c55e544c577f3012e31d6bb309e1f145dd9eb29f59d76